CRISPR Therapeutics AG (CRSP) Cash from Operations (2015 - 2026)
CRISPR Therapeutics AG (CRSP) reported Cash from Operations of 108897000.0 for Q1 2026, down 101.86% on a YoY basis from 5857095173.48 in Q1 2025, and down 17.66% sequentially from 92553000.0 in Q4 2025.
CRISPR Therapeutics AG (CRSP) Cash from Operations (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 12 years of Cash from Operations data on file, last reported at 108897000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 101.86% year-over-year to 108897000.0; the trailing twelve-month figure through Mar 2026 stood at 399964000.0 (down 30.51% YoY), and the FY2025 full-year result was 345014000.0, down 141.65% from the prior year.
- Cash from Operations fell to 108897000.0 in Q1 2026, from 92553000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 109752000.0 in Q1 2024 to a low of 141956000.0 in Q2 2022.
- A 5-year average of 79576529.41 and a median of 96073000.0 in 2023 frame the typical range for Cash from Operations.
- Peak annual rise in Cash from Operations reached 1147.32% in 2024, while the deepest fall reached 168.25% in 2024.
- Tracing CRSP's Cash from Operations over 5 years: stood at 113328000.0 in 2022, then gained by 15.23% to 96073000.0 in 2023, then soared by 47.92% to 50031000.0 in 2024, then slumped by 84.99% to 92553000.0 in 2025, then declined by 17.66% to 108897000.0 in 2026.
- Business Quant data shows CRSP's Cash from Operations at 108897000.0 in Q1 2026, 92553000.0 in Q4 2025, and 84634000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | -108.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -108.90 Mn |
| Mar 31, 2026 | -108.90 Mn |
| Dec 31, 2025 | -92.55 Mn |
| Dec 31, 2025 | -92.55 Mn |
| Sep 30, 2025 | -84.63 Mn |
| Sep 30, 2025 | -84.63 Mn |
| Jun 30, 2025 | -113.88 Mn |
| Jun 30, 2025 | -113.88 Mn |
| Mar 31, 2025 | -53.95 Mn |
| Mar 31, 2025 | -53.95 Mn |
| Dec 31, 2024 | -50.03 Mn |
| Dec 31, 2024 | -50.03 Mn |
| Sep 30, 2024 | -106.91 Mn |
| Sep 30, 2024 | -106.91 Mn |
| Jun 30, 2024 | -95.58 Mn |
| Jun 30, 2024 | -95.58 Mn |
| Mar 31, 2024 | 109.75 Mn |
| Mar 31, 2024 | 109.75 Mn |
| Dec 31, 2023 | -96.07 Mn |
| Dec 31, 2023 | -96.07 Mn |